KR890001565A - 활성성분으로 3- 벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸) 아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약 - Google Patents

활성성분으로 3- 벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸) 아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약 Download PDF

Info

Publication number
KR890001565A
KR890001565A KR1019880009321A KR880009321A KR890001565A KR 890001565 A KR890001565 A KR 890001565A KR 1019880009321 A KR1019880009321 A KR 1019880009321A KR 880009321 A KR880009321 A KR 880009321A KR 890001565 A KR890001565 A KR 890001565A
Authority
KR
South Korea
Prior art keywords
active ingredient
injection drug
butanoyloxy
benzoyloxy
chloroethyl
Prior art date
Application number
KR1019880009321A
Other languages
English (en)
Other versions
KR900006983B1 (ko
Inventor
기로 아사노
사또시 미쯔하시
겐지 반나이
히사유끼 와다
후미오 다무라
Original Assignee
스가노 요리쓰구
구레하 가가꾸 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스가노 요리쓰구, 구레하 가가꾸 고교 가부시끼가이샤 filed Critical 스가노 요리쓰구
Publication of KR890001565A publication Critical patent/KR890001565A/ko
Application granted granted Critical
Publication of KR900006983B1 publication Critical patent/KR900006983B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

활성성분으로 3-벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸)아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 활성성분으로 3-벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸)아미노)페닐)부타노일옥시]아세테이트를 요오드화된 엥속유 지방산의 에스테르중 용해시켜 제조된 주사약.
  2. 제1항에 있어서, 상기 활성성분으로 3-벤조일옥시-1,3,5(10)-17β-[4-(p-비스(2-클로로에틸)아미노)페닐)부타노일옥시]아세테이트인 주사약.
  3. 제1항에 있어서, 상기 활성성분의 투여량이 0.05 내지 10mg/kg 체중인 주사약.
  4. 제1항에 있어서, 상기 주사약이 동맥내 주사약인 주사약.
  5. 제1항에 있어서, 상기 주사약이 항종양재인 주사약.
  6. 제1항에 있어서, 상기 요오드화된 앵속유 지방산의 에스테르가 36 내지 40%의 요오드화를 갖는 요오드회된 앵속유 지방산의 에틸에스테르인 주사약.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880009321A 1987-07-22 1988-07-22 활성성분으로 3-벤조일옥시-1, 3, 5(10)-에스트라트리엔-17-[4-(p-(비스(2-클로로에틸)아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약 KR900006983B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP182842/87 1987-07-22
JP62182842A JPH0794377B2 (ja) 1987-07-22 1987-07-22 エストラジオール誘導体を含有する注射剤
JP62-182842 1987-07-22

Publications (2)

Publication Number Publication Date
KR890001565A true KR890001565A (ko) 1989-03-27
KR900006983B1 KR900006983B1 (ko) 1990-09-25

Family

ID=16125411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880009321A KR900006983B1 (ko) 1987-07-22 1988-07-22 활성성분으로 3-벤조일옥시-1, 3, 5(10)-에스트라트리엔-17-[4-(p-(비스(2-클로로에틸)아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약

Country Status (8)

Country Link
US (1) US4921849A (ko)
EP (1) EP0300749B1 (ko)
JP (1) JPH0794377B2 (ko)
KR (1) KR900006983B1 (ko)
CA (1) CA1315682C (ko)
DE (1) DE3887401T2 (ko)
PH (1) PH26286A (ko)
ZA (1) ZA885227B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352595B2 (en) 2016-05-18 2022-06-07 Lg Electronics Inc. Beverage making apparatus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2520074B2 (ja) * 1992-06-11 1996-07-31 呉羽化学工業株式会社 新規なエストラジオ―ル誘導体−クロラムブチル結合体、その製造方法、及び医薬製剤
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810397B2 (ja) * 1978-12-08 1983-02-25 呉羽化学工業株式会社 新規なエストラジオ−ル誘導体とその製造方法及び抗腫瘍剤
US4261910A (en) * 1978-08-14 1981-04-14 Kureha Kagaku Kogyo Kabushiki Kaisha Process for the preparation of Chlorambucil derivatives
JPS5842880B2 (ja) * 1980-01-28 1983-09-22 呉羽化学工業株式会社 新規なエストラジオ−ル誘導体とその抗腫瘍剤
JPS56110700A (en) * 1980-02-08 1981-09-01 Kureha Chem Ind Co Ltd Estradiol-17alphaderivative and ist antitumor agent
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS58124714A (ja) * 1982-01-20 1983-07-25 Yamanouchi Pharmaceut Co Ltd 抗腫瘍物質の油性組成物
JPS61189215A (ja) * 1985-02-18 1986-08-22 Teijin Ltd ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物
JPH0621072B2 (ja) * 1986-11-12 1994-03-23 呉羽化学工業株式会社 エストラジオ−ル誘導体よりなる免疫調節剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352595B2 (en) 2016-05-18 2022-06-07 Lg Electronics Inc. Beverage making apparatus

Also Published As

Publication number Publication date
AU592708B2 (en) 1990-01-18
KR900006983B1 (ko) 1990-09-25
EP0300749A2 (en) 1989-01-25
JPH0794377B2 (ja) 1995-10-11
JPS6426595A (en) 1989-01-27
CA1315682C (en) 1993-04-06
AU1971088A (en) 1989-01-27
US4921849A (en) 1990-05-01
PH26286A (en) 1992-04-10
EP0300749B1 (en) 1994-01-26
ZA885227B (en) 1989-03-29
DE3887401D1 (de) 1994-03-10
DE3887401T2 (de) 1994-05-11
EP0300749A3 (en) 1990-01-31

Similar Documents

Publication Publication Date Title
DE59008336D1 (de) Orale Lipidarzneiform.
KR960000219A (ko) 당뇨병 합병증 치료용 조성물
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR890001533A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
NO176082C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel
KR850004389A (ko) 경피침투가 증진된 생리학적 활성제제의 제조방법
KR920700655A (ko) 주사가능한 클라리트로마이신 조성물
KR970025615A (ko) 암 전이 억제제
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ATE69724T1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
BR8800763A (pt) Processo para a preparacao de um produto de efeito retardado contendo diltiazem,para uma unica administracao diaria
KR890003388A (ko) 경구투여용 에리스로 마이신 조성물
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
KR890001565A (ko) 활성성분으로 3- 벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸) 아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR920702225A (ko) 약학 조성물
KR890004705A (ko) 항바이러스성 제제
KR890014109A (ko) 의약제
KR830009776A (ko) 세포 보호 유도방법
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
KR870011135A (ko) 시스-6-(4-아세트아닐리도)-8,9-디메톡시-2-메틸-1,2,3,4,4a,10b- 헥사이드로-벤조〔c〕〔1,6〕 나프티리딘으로 구성된 약학적 조성물 및 그것의 용도
KR890011594A (ko) 4-아로일이미다졸-2-온의 제약 조성물
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR950016756A (ko) 피로회복제 조성물

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970822

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee